Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro

American Journal of Surgery

Volumn 186, Issue 5, 2003, Pages 431-436

  Durkin, Alan J ^a   Bloomston, P Mark ^a   Rosemurgy, Alexander S ^a   Giarelli, Natalie ^a   Cojita, Diane ^a   Yeatman, Timothy J ^a   Zervos, Emmanuel E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Immunohistochemistry; Pancreatic cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GENE PRODUCT; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PANCREAS CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0242361300     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.07.008     Document Type: Article

References (17)

1. Murphy L.O., Cluck M.W., Lovas S., et al. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer. 84:2001;926-935.
2. Matsuda K., Idezawa T., You X.J., et al. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res. 62:2002;5611-5617.
3. Bruns C.J., Solorzano C.C., Harbison M.T., et al. Blockade of epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60:2000;2926-2935.
4. Solorzano C.C., Baker C.H., Tsan R., et al. Optimization for the blockade of epidermal growth factor receptor signalling for therapy of human pancreatic carcinoma. Clin Cancer Res. 7:2001;2563-2572.
5. Balsega J., Pfister M.R., Cooper R., et al. Phase 1 studies of anti-epidermal growth factor receptor chimeric antibody c225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914.
6. Wolff R.A. Exploiting molecular targets in pancreatic cancer. Hematol Oncol Clin North Am. 16:2002;96-111.
7. Xiong H.G., Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 29:2002;31-37.
8. Boonstra J., Rijken P., Humbel B., et al. The epidermal growth factor. Cell Biol Int. 19:1995;413-431.
9. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279.
10. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 6:2000;1936-1948.
11. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
12. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3:1997;2703-2707.
13. Lee L.T., Huang Y.T., Hwang J.J., et al. Blockade of epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 22:2002;1615-1628.
14. Allred D.C., Harvey J.M., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:1998;155-168.
15. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGF receptor tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892.
16. Yamanaka Y., Friess H., Kobrin M.S., et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:1993;565-569.
17. Baker C.H., Kedar D., McCarty M.F., et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol. 161:2002;929-938.